

Perleux® Nuvea is a BDDE-free stabilized injectable hyaluronic acid (HA) product indicated for facial treatment and adipose tissue restoration, resulting in improved skin firmness and visibly youthful skin. It combines both High molecular weight hyaluronic acid (H-HA) and Low molecular weight hyaluronic acid (L-HA) to deliver intense skin hydration, rejuvenation, and enhanced elasticity.

Indications
Perleux® Nuvea is indicated for:
•Facial skin rejuvenation and restoration of adipose tissue in patients with facial volume deficiency and for individuals presenting with skin laxity and tissue descent.
• Dermal tissue repair in cases of acne scars
• Correction and filling of natural and induced skin depressions
• Rehydration and improvement of skin tone and elasticity, especially in cases of:
- Aging
- Excessive dehydration
- Weight loss
- Compensation for the reduction of endogenous HA

Advantages of Perleux® Nuvea
• High HA Concentration
50 mg H-HA + 50 mg L-HA in a 2 mL syringe for optimal hydration and rejuvenation.
• Specific Manufacturing Technology
The H-HA and L-HA chains contained in Perleux® Nuvea interact with each other, providing unique rheological characteristics and allowing the administration of higher concentrations of HA without increasing viscosity.
• Skin Rejuvenation and Repair
Ideal for combating the physiological decrease of HA in the skin, it helps restore hydration, elasticity, and tone by synergistically combining deep hydration with the mechanical lifting action on skin depressions.
• High Safety and Tolerability
Sterile, pyrogen-free formula, with no chemical cross-linker (BDDE-free).

Perleux® Nuvea Packaging
Perleux® Nuvea is available in packages containing one prefilled syringe (PFS) with the following volume: 50 mg (H-HA) + 50 mg (L-HA) of hyaluronic acid in 2 mL phosphate-buffered saline solution.



Perleux® Nuvea Treatment Protocol
It is advisable to perform an initial cycle of two treatment sessions at 30-day intervals, if necessary, followed by maintenance treatments every 4 months.

Recommended Injection Technique: Nuvea-Lift
The injection entry point is located approximately 2.5 cm anterior to the superior border of the tragus. The product is administered into the subcutaneous plane on each side of the face using 1 to 4 linear injection vectors, according to the physician's clinical judgment and the patient's anatomical characteristics.
The uppermost injection vector is directed tangentially along the inferior border of the zygomatic arch, while the lowermost vector follows the course of the mandibular ramus. Two additional vectors may be placed between these two reference lines to optimize product distribution throughout the treatment area.
A volume of 0.25-1mL is injected along each vector.
A 21- or 22-gauge cannula, 5 cm in length, is preferred over a needle to minimize the risk of vascular injury. Cannula injections are associated with lower odds of vascular compromise or occlusion events (77.1% lower odds of occlusion), especially when treating high-risk areas such as the preauricular region.

Recommended Treatment Volume
Depending on the facial morphology, 2-4 mL (equivalent to 1-2 PFS) is used per treatment session. In individuals with an atrophic facial appearance and reduced fat volume, up to 2 mL may be injected per side of the face.



Recommended Age Range
Perleux® Nuvea is indicated for adult males and females aged 18 years and older, at the physician's discretion.

Contraindications
Perleux® Nuvea must not be used:
• In patients with active inflammation (skin eruptions such as cold sores, cysts, pimples, rashes, or hives) or infection at the injection site.
• In conjunction with treatments such as laser resurfacing and medium-deep peeling.
• In individuals with a history of anaphylaxis or multiple severe allergies.
• In patients with bleeding disorders and recent anticoagulant/antiplatelet use.
• In individuals with a history of hypersensitivity to gram-positive bacterial proteins.

Orchid Pharmed Sky's the Limit
ESPAD injectif luxe
ISO 9001:2015
ISO 13485:2016

References
1. Perleux® Nuvea brochure, Espad Pharmed.
2. UpToDate. Hyaluronate derivatives: Drug Information. Wolters Kluwer; July 2026.
3. Alam M, Kakar R, Dover JS, Harikumar V, Kang BY, Wan HT, Poon E, Jones DH. Rates of vascular occlusion associated with using needles vs cannulas for filler injection. JAMA dermatology. 2021 Feb;157(2):174-80.
Customer Service: +982143473030